Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
872 articles with Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a virtual investor day on Thursday, December 9th at 11:00 a.m. Eastern Time.
Ionis Pharmaceuticals, Inc. today announced that Pfizer has provided an update on the Phase 2b study of vupanorsen, formerly IONIS-ANGPTL3-L.
A cardiovascular drug Pfizer licensed from Akcea Therapeutics in 2019 hit the mark in a Phase IIb dose-ranging study in patients with elevated non-HDL-C and triglycerides.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE, the registrational study in the donidalorsen (formerly IONIS-PKK-LRx) Phase 3 clinical program.
Ionis' antisense therapies to be featured at the American Heart Association (AHA) Scientific Sessions 2021
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced the upcoming presentations of clinical and non-clinical data from its cardiovascular pipeline, including several of its investigational antisense medicines for cardiovascular disease, at the American Heart Association Scientific Sessions, to be held virtually Nov. 13-15, 2021.
Ionis Pharmaceuticals, Inc. announced that management will participate in virtual fireside chats at the following virtual investor conferences:.
Phase 2 study results of Ionis' novel antisense treatment for hereditary angioedema to be presented at ACAAI annual meeting
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced that positive results from the Phase 2 study of its investigational antisense medicine, donidalorsen, will be presented at the American College of Asthma, Allergy & Immunology Annual Scientific Meeting in New Orleans and via livestream, November 4-8.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the three and nine months ended September 30, 2021 and recent business achievements.
Ionis initiates pivotal Phase 3 clinical study of olezarsen in patients with severe hypertriglyceridemia
Ionis Pharmaceuticals, Inc. announced today the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-LRx.
Webcast scheduled for Wednesday, November 3 at 11:30 a.m. Eastern Time
Biogen announced topline results from the Phase III VALOR trial of tofersen for superoxide dismutase 1 amyotrophic lateral sclerosis.
Ionis Pharmaceuticals, Inc. partner Biogen announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 amyotrophic lateral sclerosis.
Ionis to host ATTR symposium highlighting CARDIO-TTRansform Study at 3rd European ATTR Amyloidosis meeting
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced it will present 14 posters and two symposiums highlighting new scientific insights from its ATTR amyloidosis portfolio at the 3rd European ATTR Amyloidosis meeting for Patients and Doctors on September 6-8, 2021.
Ionis Pharmaceuticals, Inc. announced that management will present a company overview at the following virtual investor conferences:.
While treatments exist to manage the symptoms of the disease, nothing has proven to be curative – yet. Several biopharma companies are working hard to change that.
Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics' technology potentially expands LICA technology capabilities Webcast , August 4, 2021, at 11:30 a.m. Eastern Time.
Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that pelacarsen, formerly known as AKCEA-APO(a)-LRx, and licensed by Novartis (NYSE: NVS) for exclusive worldwide development and commercialization, continues to advance in the clinic as the potential first-in-class treatment for lipoprotein(a) or Lp(a)-driven cardiovascular disease.
Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapies, announced it has completed enrollment of NEURO-TTRansform, the company's Phase 3 study of eplontersen, formerly AKCEA-TTR-LRx, for people with hereditary transthyretin-mediated amyloid polyneuropathy.
One of the eagerly anticipated presentations at the AAIC being held this week is Biogen and its partner Eisai on their controversial drug ADUHELM™ (aducanumab). Biogen is also presenting new data on a different Alzheimer’s drug with another partner, Ionis Pharmaceuticals.
Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC
Biogen Inc. (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that topline data from a Phase 1b placebo-controlled, multiple ascending dose clinical study showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and tolerability in patients with mild Alzheimer's disease.